The protective effect of immunoglobulin in murine tuberculosis is dependent on IgG glycosylation

Pathogens and Disease

Volumn 69, Issue 3, 2013, Pages 176-183

  Olivares, Nesty ^a,b   Marquina, Brenda ^a   Mata Espinoza, Dulce ^a   Zatarain Barron, Zyanya L ^a   Pinzón, Clara Espitia ^b   Estrada, Iris ^c   Parada, Cristina ^b   Collin, Mattias ^d   Rook, Graham ^e   Hernandez Pando, Rogelio ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^d LUND UNIVERSITY   (Sweden)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antibodies; Experimental models; Glycosylation; Immunotherapy; IVIG; Tuberculosis

Indexed keywords

DEGLYCOSYLATED IMMUNOGLOBULIN G; GLYCAN; GLYCOSYLATED IMMUNOGLOBULIN G; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; MYCOBACTERIUM ANTIGEN; N ACETYL BETA GLUCOSAMINIDASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN RECOGNITION; ARTICLE; BACTERIAL LOAD; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; LUNG GRANULOMA; LUNG INJURY; LUNG TUBERCULOSIS; MALE; MOUSE; MURINE MODEL; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; TRACHEOBRONCHIAL TOILET; WESTERN BLOTTING;

ANTIBODIES; EXPERIMENTAL MODELS; GLYCOSYLATION; IMMUNOTHERAPY; IVIG; TUBERCULOSIS;

ANIMALS; ANTIGENS, BACTERIAL; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; INFUSIONS, PARENTERAL; MALE; MICE; MYCOBACTERIUM TUBERCULOSIS; POLYSACCHARIDES; TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

EID: 84896781254     PISSN: None     EISSN: 2049632X     Source Type: Journal    
DOI: 10.1111/2049-632X.12069     Document Type: Article

References (40)

1. Abdou NI, Greenwell CA, Mehta R, Narra M, Hester JD & Halsey JF (2009) Efficacy of intravenous gammaglobulin for immunoglobulin G subclass and/or antibody deficiency in adults. Int Arch Allergy Immunol 149: 267-274.
2. Achkar JM & Casadevall A (2013) Antibody-mediated immunity against tuberculosis: implications for vaccine development. Cell Host Microbe 13: 250-262.
3. Allhorn M & Collin M (2009) Sugar-free antibodies-the bacterial solution to autoimmunity? Ann NY Acad Sci 1173: 664-669.
4. Andersen JT, Foss S, Kenanova VE, Olafsen T, Leikfoss IS, Roopenian DC, Wu AM & Sandlie I (2012) Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life. J Biol Chem 287: 22927-22937.
5. Anthony RM & Ravetch JV (2010) A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol 30(suppl 1): S9-S14.
6. Anthony RM, Wermeling F, Karlsson MC & Ravetch JV (2008) Identification of a receptor required for the anti-inflammatory activity of IVIg. P Natl Acad Sci USA 105: 19571-19578.
7. Anthony RM, Kobayashi T, Wermeling F & Ravetch JV (2011) Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 475: 110-113.
8. Collin M & Olsén A (2001a) Effect of SpeB and EndoS from Streptococcus pyogenes on human immunoglobulins. Infect Immun 69: 7187-7189.
9. Collin M & Olsén A (2001b) EndoS, a novel secreted protein from Streptococcus pyogenes with endoglycosidase activity on human IgG. EMBO J 20: 3046-3055.
10. Collin M, Shannon O & Björck L (2008) IgG glycan hydrolysis by a bacterial enzyme as a therapy against autoimmune conditions. P Natl Acad Sci USA 105: 4265-4270.
11. Glatman-Freedman A (2006) The role of antibody-mediated immunity in defense against Mycobacterium tuberculosis: advances toward a novel vaccine strategy. Tuberculosis (Edinb) 86: 191-197.
12. Glatman-Freedman A (2010) The role of antibodies against tuberculosis. The Art and Science of Tuberculosis Vaccine Development (Mohd-Nor N, Acosta A, & Sarmiento ME, eds), pp. 81-107. Selangor Durul Ehsan, Malaysia. Oxford Fajar Sdn.
13. Global Octapharma Plasma donation centers. Available at: http://www.octapharma.com. Revised 10/06/2013.
14. Hamasur B, Haile M, Pawlowski A, Schroder U, Kallenius G & Svenson SB (2004) A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab')2 fragment prolong survival of mice infected with Mycobacterium tuberculosis. Clin Exp Immunol 138: 30-38.
15. Hernández-Pando R, Orozcoe H, Sampieri A, Pavón L, Velasquillo C, Larriva-Sahd J et al. (1996) Correlation between the kinetics of Th1, Th2 cells and pathology in a murine model of experimental pulmonary tuberculosis. Immunology 89: 26-33.
16. Hodoniczky J, Zheng YZ & James DC (2005) Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog 21: 1644-1652.
17. Joller N, Weber SS, Müller AJ, Spörri R, Selchow P, Sander P, Hilbi H & Oxenius A (2010) Antibodies protect against intracellular bacteria by Fc receptor-mediated lysosomal targeting. P Natl Acad Sci USA 107: 20441-20446.
18. Käsermann F, Boerema DJ, Rüegsegger M, Hofmann A, Wymann S, Zuercher AW & Miescher S (2012) Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIg) after lectin fractionation. PLoS ONE 7: e37243.
19. López Y, Yero D, Falero-Diaz G, Olivares N, Sarmiento ME, Sifontes S et al. (2009) Induction of a therapeutic response with an IgA monoclonal antibody against Mycobacterium tuberculosis 16 kDa protein in a model of progressive pulmonary infection. Int J Med Microbiol 299: 447-452.
20. Magy L (2012) Current indications of polyvalent immunoglobulins. Bull Acad Natl Med 196: 49-60.
21. Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA & Sim RB (1995) Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med 1: 237-243.
22. McClelland EE, Nicola AM, Prados-Rosales R & Casadevall A (2010) Ab binding alters gene expression in Cryptococcus neoformans and directly modulates fungal metabolism. J Clin Invest 120: 1355-1361.
23. McCulloch J, Zhang YW, Dawson M, Harkiss GD, Peterhans E, Vogt HR, Lydyard PM & Rook GA (1995) Glycosylation of IgG during potentially arthritogenic lentiviral infections. Rheumatol Int 14: 243-248.
24. Nimmerjahn F & Ravetch JV (2005) Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310: 1510-1512.
25. Nimmerjahn F & Ravetch JV (2008) Fc gamma receptors as regulators of immune responses. Nat Rev Immunol 8: 34-47.
26. Olivares N, León A, López Y, Puig A, Cádiz A, Falero G et al. (2006) The effect of the administration of human gamma globulins in a model of BCG infection in mice. Tuberculosis (Edinb) 86: 268-272.
27. Olivares N, Puig A, Aguilar D, Moya A, Cádiz A, Otero O et al. (2009) Prophylactic effect of administration of human gamma globulins in a mouse model of tuberculosis. Tuberculosis (Edinb) 89: 218-220.
28. Parekh R, Isenberg D, Rook G, Roitt I, Dwek R & Rademacher T (1989) A comparative analysis of disease-associated changes in the galactosylation of serum IgG. J Autoimmun 2: 101-114.
29. Rademacher TW, Williams P & Dwek RA (1994) Agalactosyl glycoforms of IgG autoantibodies are pathogenic. P Natl Acad Sci USA 91: 6123-6127.
30. Roy E, Stavropoulos E, Brennan J, Coade S, Grigorieva E, Walker B et al. (2005) Protective efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice. Infect Immun 73: 6101-6109.
31. Scallon BJ, Tam SH, McCarthy SG, Cai AN & Raju TS (2007) Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol Immunol 44: 1524-1534.
32. Shashidharamurthy R, Bozeman E, Patel J, Kaur R, Meganathan J & Selvaraj P (2010) Analysis of cross-species IgG binding to human and mouse Fc gamma receptors (FcgammaRs). J Immunol 184: 138.29.
33. Stadlmann J, Pabst M & Altmann F (2010) Analytical and functional aspects of antibody sialylation. J Clin Immunol 30(suppl 1): S15-S19.
34. Surkova LK & Dius'mikeeva MI (2003) Acutely progressive pulmonary tuberculosis: morphological and bacteriological features. Probl Tuberk 3: 33-35.
35. Teitelbaum R, Glatman-Freedman A, Chen B, Robbins JB, Unanue E, Casadevall A et al. (1998) A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. P Natl Acad Sci USA 95: 15688-15693.
36. Williams A, Reljic R, Naylor I, Clark SO, Falero-Diaz G, Singh M et al. (2004) Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs. Immunology 111: 328-333.
37. World Health Organization (2012) Global tuberculosis report 2012.
38. Xolalpa W, Vallecillo AJ, Lara M, Mendoza-Hernandez G, Comini M, Spallek R et al. (2007) Identification of novel bacterial plasminogen-binding proteins in the human pathogen Mycobacterium tuberculosis. Proteomics 7: 3332-3341.
39. Zhou T, Chen Y, Hao L & Zhang Y (2006) DC-SIGN and immunoregulation. Cell Mol Immunol 3: 279-283.
40. Zhou Q, Shankara S, Roy A, Qiu H, Estes S, McVie-Wylie A, Culm-Merdek K, Park A, Pan C & Edmunds T (2008) Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol Bioeng 99: 652-665.